Brinda Kamalia

MedicineImmunology and MicrobiologyBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2”.

Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2

Cell Reports(2021)10.1016/j.celrep.2021.108959

N/A

0DataRank · unranked

250 citations

Jae Seung Lee, Kanupriya Whig, Elisha Segrist, Minghua Li, Brinda Kamalia +12 more

Pharmacological activation of STING blocks SARS-CoV-2 infection

Science Immunology(2021)10.1126/sciimmunol.abi9007

N/A

0DataRank · unranked

193 citations

Max Ferretti, Baoling Ying, Hélène C. Descamps, Emily M. Lee, Mark Dittmar +15 more

Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2

Nature(2022)10.1038/s41586-022-04482-x

N/A

0DataRank · unranked

202 citations

Robert M. Johnson, Kasirajan Ayyanathan, Jesse Miller, Kanupriya Whig, Brinda Kamalia +17 more

Nucleoside analogs NM107 and AT-527 are antiviral against rubella virus

PNAS Nexus(2023)10.1093/pnasnexus/pgad256

N/A

0DataRank · unranked

9 citations

Kanupriya Whig, Jesse Miller, Brinda Kamalia, Suganthi Suppiah, Ludmila Perelygina +4 more